Apolipoprotein B antisense inhibition -update on mipomersen

Current Pharmaceutical Design

Volumn 19, Issue 17, 2013, Pages 3132-3142

  Gebhard, Catherine ^a   Huard, Gabriel ^a   Kritikou, Ekaterini A ^a   Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antisense oligonucleotides; Apolipoprotein B; Familial hypercholesterolemia; Mipomersen

Indexed keywords

ANACETRAPIB; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; EPROTIROME; EVACETRAPIB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; MIPOMERSEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; PROTEIN INHIBITOR; SIMVASTATIN; SQUALENE SYNTHASE INHIBITOR; THYROID HORMONE DERIVATIVE; TORCETRAPIB;

ACUTE HEART INFARCTION; ANGINA PECTORIS; APHERESIS; ARTICLE; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LIFESTYLE MODIFICATION; LIPID METABOLISM; LIVER TOXICITY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSTABLE ANGINA PECTORIS; VARIANT ANGINA PECTORIS;

EID: 84876802101     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990312     Document Type: Article

References (89)

1. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-90.
2. Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 2011; 378: 2013-20.
3. Hsia J, MacFadyen JG, Monyak J, et al. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol 2011; 57: 1666-75.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
5. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
6. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
7. Martin SS, Metkus TS, Horne A, et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol 2012; 110: 307-13.
8. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
9. Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.
10. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25: 49-68.
11. Marks D, Thorogood M, Neil HA, et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14.
12. Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007; 18: 397-400.
13. Burnett JR. Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006; 8: 461-7.
14. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-19.
15. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499-506.
16. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008; 372: 224-33.
17. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by onstudy lipid levels? Circulation 2002; 105: 1162-9.
18. Kastelein JJ, van der Steeg WA, Holme I, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008; 117: 3002-9.
19. Crooke RM. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 2005; 5: 907-17.
20. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebocontrolled trial. Lancet 2010; 375: 998-1006.
21. Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010; 105: 1413-9.
22. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by shortterm administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-35.
23. Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3 Suppl): S9-17.
24. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173: 55-68.
25. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007; 116: 664-8.
26. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin Vasc Med 2004; 4: 43-50.
27. Hudgins LC, Gordon BR, Parker TS, et al. LDL Apheresis: an effective and safe treatment for refractory hypercholesterolemia. Cardiovasc Drug Rev 2002; 20: 271-80.
28. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010; 17: 667-74.
29. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-803.
30. Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-91.
31. Thompson GR. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198: 247-55.
32. Tavridou A, Ragia G, Manolopoulos VG. Emerging targets for the treatment of dyslipidemia. Curr Med Chem 2011; 18: 909-22.
33. Cohen JC, Boerwinkle E, Mosley TH, Jr., et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354: 1264-72.
34. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 2008; 105: 11915-20.
35. Duff CJ, Scott MJ, Kirby IT, et al. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J 2009; 419: 577-84.
36. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 2009; 106: 9820-5.
37. Kohli P, Desai NR, Giugliano RP, et al. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebocontrolled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. Clin Cardiol 2012; 35: 385-91.
38. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia. N Engl J Med 2012; 367: 1891-900.
39. Sullivan D, Olsson AG, Scott R, et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients: The GAUSS Randomized Trial. JAMA 2012; 1-10.
40. Ito BR, Zhang BH, Cable EE, et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009; 156: 454-65.
41. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-16.
42. Sweetlove G. Phase III trial of eprotirome: discontinued for safety concerns Pharmaceutical Medicine [Trial Report] 2012; 26: 3.
43. Taub R, Chiang E, Kelly M, et al. Pharmacokinetics, safety and cholesterol lowering in healthy volunteers treated with single and multiple doses of Madrigal's 3196 liver-directed thyroid hormone receptor-ß Agonist. AHA Scientific Sessions Nov 06, 2012 Los Angeles.
44. Barter PJ, Brewer HB, Jr., Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 160-7.
45. Duivenvoorden R, Fayad ZA. Safety of CETP inhibition. Curr Opin Lipidol 2012; 23: 518-24.
46. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
47. Landmesser U, von Eckardstein A, Kastelein J, et al. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J 2012; 33: 1712-5.
48. Rhainds D, Arsenault BJ, Brodeur MR, et al. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiol 2012; 8: 513-31.
49. Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258: 999-1001.
50. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356: 148-56.
51. Segrest JP, Jones MK, De Loof H, et al. Structure of apolipoprotein B-100 in low density lipoproteins. J Lipid Res 2001; 42: 1346-67.
52. Dashti N, Gandhi M, Liu X, et al. The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry 2002; 41: 6978-87.
53. Mora S, Glynn RJ, Boekholdt SM, et al. On-treatment non-highdensity lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). J Am Coll Cardiol 2012; 59: 1521-8.
54. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol (Oxf) 2009; 70: 815-28.
55. Toth PP. Antisense therapy and emerging applications for the management of dyslipidemia. J Clin Lipidol 2011; 5: 441-9.
56. Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010; 12: 58-65.
57. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-44.
58. Crooke ST. An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev 1998; 8: 115-22.
59. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2009; 5: 381-91.
60. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118: 743-53.
61. Ricotta DN, Frishman W. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia. Cardiol Rev 2012; 20: 90-5.
62. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93.
63. Altmann KH, Fabbro D, Dean NM, et al. Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 1996; 24: 630-7.
64. Watanabe TA, Geary RS, Levin AA. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006; 16: 169-80.
65. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009; 77: 910-9.
66. Yu RZ, Kim TW, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007; 35: 460-8.
67. Geary RS, Yu RZ, Watanabe T, et al. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2'-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab Dispos 2003; 31: 1419-28.
68. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011; 32: 2650-9.
69. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-Omethoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009; 48: 39-50.
70. Mullick AE, Fu W, Graham MJ, et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptordeficient mice. J Lipid Res 2011; 52: 885-96.
71. Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010; 55: 1611-8.
72. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010; 51: 1057-62.
73. Feingold KR. Does inhibition of apolipoprotein B synthesis produce foie gras? J Lipid Res 2010; 51: 877-8.
74. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33: 1142-9.
75. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126: 2283-92.
76. Santos R. Long-term safety and efficacy of mipomersen in patients with familial hypercholesterolemia not controlled by maximally tolerated lipid lowering therapy. XVI International Symposium on Atherosclerosis (ISA 2012); 25-29 March 2012; Sydney, Australia.2012.
77. McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebocontrolled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012; 7: e49006.
78. Cromwell WC, Thomas GS, Boltje I, et al. Safety and efficacy of mipomersen administered as add-on therapy in patients with hypercholesterolemia and high cardiovascular risk. J Am Coll Cardiol 2011; 57 (E504).
79. Schonfeld G, Patterson BW, Yablonskiy DA, et al. Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis. J Lipid Res 2003; 44: 470-8.
80. Tanoli T, Yue P, Yablonskiy D, et al. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intraabdominal adipose tissue, and insulin sensitivity. J Lipid Res 2004; 45: 941-7.
81. Abel T, Feher J, Dinya E, et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009; 15: MS6-11.
82. Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, et al. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006; 23: 1643-7.
83. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
84. Mihaila RG, Nedelcu L, Fratila O, et al. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology 2009; 56: 1117-21.
85. Hyogo H, Ikegami T, Tokushige K, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res 2011; 41: 1057-65.
86. FDA briefing document (October 18, 2012).
87. Genzyme. FDA advisory committee recommends KYNAMRO™ for homozygous familial hypercholesterolemia. Cambridge, Mass.: Genzyme; [cited 2012 October 20, 2012]; http://www.businesswire.com/news/genzyme/20121018006758/en.
88. Shen X, Wang W, Wang L, et al. Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes. Atherosclerosis 2012; 222: 154-7.
89. Tadin-Strapps M, Peterson LB, Cumiskey AM, et al. siRNAinduced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 2011; 52: 1084-97.